Dr. Kaklamani on the Evolution of Oral SERDs in ER+ Breast Cancer

Virginia G. Kaklamani, MD, professor of medicine, Division of Hematology/Oncology, University of Texas (UT) Health San Antonio, leader, Breast Cancer Program, UT Health San Antonio MD Anderson Cancer Center, discusses the evolution of oral selective estrogen receptor degraders (SERDs) in estrogen receptor (ER)–positive breast cancer.

The evolution of oral SERDs has led to excitement regarding the tolerability and safety profile of this class of agents, Kaklamani says. Additionally, oral SERDs have shown sensitivity in patients with ESR1 mutations, addressing an unmet need in this field, Kaklamani explains.

There is significant excitement regarding the potential approval of oral SERDs, as well as their investigation in combination with other agents, Kaklamani continues. Ongoing trials are currently looking at the benefit of combining oral SERDs with CDK4/6 inhibitors, what setting oral SERDs should be used in, and how this will shape the field of ER-positive breast cancer, Kaklamani concludes.

Funding supported by Stemline Therapeutics. Content independently developed by OncLive